Olivier Elemento: A step forward in pooled CRISPR screening in PDTOs
Olivier Elemento, Director of Englander Institute for Precision Medicine at Weill Cornell Medicine, shared an article authored by Florencia P. Madorsky Rowdo and colleagues on LinkedIn:
“In non-AI news, I am excited to share just published work from our team at the Englander Institute. The research described in this new paper in the journal Cancer Research is a significant step forward in pooled CRISPR screening in patient-derived tumor organoids (PDTOs) – bringing us closer to functional precision medicine.
Co-led by Laura Martin, Melissa Davis, and Florencia Madorsky Rowdo, this study demonstrates the power of CRISPR-based functional genomics to uncover new therapeutic opportunities.
Key Highlights:
– One of the first pooled CRISPR screens in patient-derived organoids, overcoming technical challenges in 3D tumor models.
– Identified essential kinase dependencies that drive tumor viability, revealing potential therapeutic targets.
– Discovered synergy between EGFR and FGFR1 inhibition, opening new avenues for combination therapy.
By applying functional genomic screening in 3D patient-derived models, we can move beyond genetic alterations to directly identify druggable vulnerabilities, providing a powerful complement to traditional precision oncology approaches.
Read the full study here and preprint here.
Proud of our fantastic team and collaborators—excited to see how these findings advance CRISPR-based functional screening and cancer therapy!”
Authors: Florencia P. Madorsky Rowdo et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023